Added Value of Prostate-specific Antigen Density in Selecting Prostate Biopsy Candidates Among Men with Elevated Prostate-specific Antigen and PI-RADS ≥3 Lesions on Multiparametric Magnetic Resonance Imaging of the Prostate: A Systematic Assessment by PI-RADS Score
European Urology Focus · 2024-07 · 10 (4) · 634-640
DOI: 10.1016/j.euf.2023.10.006 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Urology Focus, 2024-07. Verfasst von Francesco Pellegrino und 16 weiteren Autor:innen. Beteiligte Einrichtung: Division of Oncology/Unit of Urology, Soldera Prostate Cancer Laboratory, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Mil…. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Prostate-Specific Antigen, Multiparametric Magnetic Resonance Imaging, Prostate. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 24 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: A significant proportion of patients with positive multiparametric magnetic resonance imaging (mpMRI; Prostate Imaging-Reporting and Data System [PI-RADS] scores of 3-5) have negative biopsy results. OBJECTIVE: To systematically assess all prostate-specific antigen density (PSAD) values and identify an appropriate cutoff for identification of patients with positive mpMRI who could potentially avoid biopsy on the basis of their PI-RADS score. DESIGN, SETTING, AND PARTICIPANTS: The study included a cohort of 1341 patients with positive mpMRI who underwent combined targeted and systematic biopsies. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Multivariable logistic regression analysis (MVA) was used to assess the association between PSAD and the risk of clinically significant prostate cancer (csPCa, grade group ≥2) after adjusting for confounders. We used locally weighted scatterplot smoothing to explore csPCa risk according to PSAD and PI-RADS scores. PSAD utility was observed only for patients with PI-RADS 3 lesions, so we plotted the effect of each PSAD value as a cutoff for this subgroup in terms of biopsies saved, csPCa cases missed, and clinically insignificant PCa (ciPCa, grade group 1) cases not detected. RESULTS AND LIMITATIONS: Overall, 667 (50%) csPCa cases were identified. On MVA, PSAD independently predicted csPCa (odds ratio 1.57; p < 0.001). For PI-RADS ≥4 lesions, the csPCa risk was ≥40% regardless of PSAD. Conversely, among patients with PI-RADS 3 lesions, csPCa risk ranged from 0% to 60% according to PSAD values, and a PSAD cutoff of 0.10 ng/ml/cm3 corresponded to a threshold probability of 10% for csPCa. Using this PSAD cutoff for patients with PI-RADS 3 lesions would have saved 32% of biopsies, missed 7% of csPCa cases, and avoided detection of 34% of ciPCa cases. Limitations include selection bias and the high experience of the radiologists and urologists involved. CONCLUSIONS: Patients with PI-RADS ≥4 lesions should undergo prostate biopsy regardless of their PSAD, while PSAD should be used to stratify patients with PI-RADS 3 lesions. Using a threshold probability of 10% for csPCa, our data suggest that the appropriate strategy is to avoid biopsy in patients with PI-RADS 3 lesions and PSAD
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Oncology/Unit of Urology, Soldera Prostate Cancer Laboratory, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy; Vita-Salute San Raffaele University, Milan, Italy. Electron…
- Division of Oncology/Unit of Urology, Soldera Prostate Cancer Laboratory, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy; Vita-Salute San Raffaele University, Milan, Italy.
- Department of Radiology, IRCCS San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy.
Zitieren
APA
Pellegrino, F., Stabile, A., Sorce, G., Quarta, L., Robesti, D., Cannoletta, D., Cirulli, G., Barletta, F., Scuderi, S., Mazzone, E., de Angelis, M., Brembilla, G., De Cobelli, F., Salonia, A., Montorsi, F., Briganti, A., & Gandaglia, G. (2024). Added Value of Prostate-specific Antigen Density in Selecting Prostate Biopsy Candidates Among Men with Elevated Prostate-specific Antigen and PI-RADS ≥3 Lesions on Multiparametric Magnetic Resonance Imaging of the Prostate: A Systematic Assessment by PI-RADS Score. European Urology Focus, 10(4), 634-640. https://doi.org/10.1016/j.euf.2023.10.006
Vancouver
Pellegrino F, Stabile A, Sorce G, Quarta L, Robesti D, Cannoletta D, et al. Added Value of Prostate-specific Antigen Density in Selecting Prostate Biopsy Candidates Among Men with Elevated Prostate-specific Antigen and PI-RADS ≥3 Lesions on Multiparametric Magnetic Resonance Imaging of the Prostate: A Systematic Assessment by PI-RADS Score. European Urology Focus. 2024;10(4):634-640. doi:10.1016/j.euf.2023.10.006
BibTeX
@article{Pellegrino2024,
author = {Pellegrino, Francesco and Stabile, Armando and Sorce, Gabriele and Quarta, Leonardo and Robesti, Daniele and Cannoletta, Donato and Cirulli, Giuseppe and Barletta, Francesco and Scuderi, Simone and Mazzone, Elio and de Angelis, Mario and Brembilla, Giorgio and De Cobelli, Francesco and Salonia, Andrea and Montorsi, Francesco and Briganti, Alberto and Gandaglia, Giorgio},
title = {Added Value of Prostate-specific Antigen Density in Selecting Prostate Biopsy Candidates Among Men with Elevated Prostate-specific Antigen and PI-RADS ≥3 Lesions on Multiparametric Magnetic Resonance Imaging of the Prostate: A Systematic Assessment by PI-RADS Score},
journal = {European Urology Focus},
year = {2024},
volume = {10},
number = {4},
pages = {634--640},
doi = {10.1016/j.euf.2023.10.006}
}
EUVIMED